Open AccessSphingosine‐1‐phosphate (S1P) receptors: Promising drug targets for treating bone‐related diseases
Author(s) -
Zhang Lincheng,
Dong Yutong,
Wang Yiran,
Hu Wenhui,
Dong Shiwu,
Chen Yueqi
Publication year - 2020
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.15155
Subject(s) - osteoimmunology , sphingosine 1 phosphate receptor , immune system , receptor , sphingosine , sphingosine 1 phosphate , bone resorption , microbiology and biotechnology , osteolysis , cancer research , bone metastasis , biology , medicine , immunology , chemistry , cancer , metastasis , rankl , surgery , activator (genetics)
Sphingosine‐1‐phosphate (S1P) is a natural bioactive lipid molecule and a common first or second messenger in the cardiovascular and immune systems. By binding with its receptors, S1P can serve as mediator of signalling during cell migration, differentiation, proliferation and apoptosis. Although the predominant role of S1P in bone regeneration has been noted in many studies, this role is not as well‐known as its roles in the cardiovascular and immune systems. In this review, we summarize previous research on the role of S1P receptors (S1PRs) in osteoblasts and osteoclasts. In addition, S1P is regarded as a bridge between bone resorption and formation, which brings hope to patients with bone‐related diseases. Finally, we discuss S1P and its receptors as therapeutic targets for treating osteoporosis, inflammatory osteolysis and bone metastasis based on the biological effects of S1P in osteoclastic/osteoblastic cells, immune cells and tumour cells.